相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The average cost to develop a new drug reached $2.23 billion in 2024, a 65% increase from 2014 (about 25% after inflation), according to Deloitte's 2025 report. - More complex medicines such as monoclonal antibodies, RNA-based therapies, and cell and gene therapies are driving up research, laboratory, and manufacturing costs. - Clinical trials have become larger and more data-heavy, with Phase 3 protocols now averaging 19 endpoints and nearly six million datapoints, up from about 929,000 in 2012. - The probability that a drug entering Phase 1 will reach market has fallen to an all-time low of 6.7%, down from 10.4% in 2014, making each failure increasingly costly.
- Deloitte's flagship R&D productivity series reports the average internal rate of return for top biopharma companies recovered to 7.0% in 2025, up from a historic low of 1.2% in 2022. - The recovery is heavily concentrated in GLP-1 therapies for obesity and diabetes; excluding these assets, the IRR falls to just 2.9%. - The average cost to bring a late-stage asset from discovery to launch has nearly doubled over sixteen years, reaching $2.67 billion per asset in 2025. - Novel mechanisms of action, representing only 28% of the late-stage pipeline, account for 53% of projected revenue, underscoring the financial premium on genuine therapeutic innovation.
- ChemE Show 2026 opens June 9-10 in Houston, bringing together pharmaceutical and petrochemical industry leaders including Eli Lilly and Johnson & Johnson to address manufacturing convergence. - The inaugural event focuses on decarbonization, digital transformation, and AI applications in chemical manufacturing, with over 100 exhibitors showcasing process technologies. - Senior leaders from major pharmaceutical companies will present on topics including biopharma manufacturing, circular chemistry, and bio-based materials development. - The conference addresses critical industry challenges that span sector boundaries, emphasizing the intersection of pharmaceutical R&D and chemical engineering innovations.
- Pharmaceutical R&D returns increased to 7% in 2025 from 5.9% in 2024, marking the third consecutive year of improvement driven primarily by GLP-1 assets targeting obesity and diabetes. - Obesity drugs now account for 25% of total forecast late-stage pipeline sales, displacing oncology as the largest contributor to pipeline value for the first time in 16 years. - GLP-1 assets represent approximately 38% of projected commercial inflows, but excluding these drugs reveals underlying R&D productivity remains weak at just 2.9%. - Average drug development costs rose to $2.67 billion in 2025 from $2.23 billion in 2024, while value concentration increases with 54 blockbuster assets projected to generate 70% of total risk-adjusted peak sales.
- bioMérieux, a global in vitro diagnostics leader, has acquired 100% of Accellix for approximately €35 million to enhance its cell and gene therapy quality control capabilities. - Accellix's compact flow cytometry platform delivers quality control results in under 30 minutes, enabling real-time monitoring during cell therapy manufacturing processes. - The acquisition completes bioMérieux's comprehensive offering for cell and gene therapies by adding cell purity and viability testing to its existing sterility, mycoplasma, and endotoxin testing portfolio. - Recent analyses indicate cell and gene therapies achieve clinical success rates two to three times higher than traditional treatments, highlighting the growing importance of rigorous quality control frameworks.
- Adalyon, a tech-bio company developing AI-powered speech biomarker platforms, has appointed Ulrik Zeuthen as CEO to drive growth in clinical trial optimization technologies. - The company's proprietary speech-based digital biomarkers aim to address the 40-50% dropout rates in clinical trials by providing non-invasive, high-frequency monitoring of cognitive and behavioral changes. - Zeuthen brings pharmaceutical industry experience from Novo Nordisk and will lead efforts to establish partnerships with pharmaceutical companies seeking to improve patient stratification and retention in clinical research.
- Nearly 60% of pharmaceutical product launches miss expectations due to fragmented data systems and outdated analysis processes, not scientific failures. - Agentic AI systems can compress market analysis from weeks to minutes by unifying scattered data sources and enabling natural language queries for strategic insights. - The technology transforms pharmaceutical market entry by providing real-time competitive assessment, promotional optimization, and geographic market analysis across the product lifecycle. - Organizations implementing AI-driven launch intelligence gain unprecedented speed and precision in strategic decision-making, creating substantial competitive advantages in delivering therapies to patients.
- Health Canada has opened a public consultation on draft guidance for decentralized clinical trials, running from December 23, 2025, to February 21, 2026, seeking input from sponsors, investigators, healthcare providers, and patients. - The draft guidance outlines regulatory considerations for trials where some or all activities occur outside traditional clinical sites using digital health technologies and virtual methods. - A comprehensive review reveals that major regulatory authorities including FDA, EMA, and NMPA have developed converging frameworks for DCTs, focusing on risk assessment, study design, digital elements, data governance, and stakeholder communication. - Research indicates DCTs can increase drug development ROI by seven-fold for Phase II and III trials while addressing diversity challenges and reducing participant burden through remote monitoring and digital health technologies.
- Medical technologist Nick Webb emphasizes that future healthcare success will depend on creating a 'beautiful human experience' alongside clinical excellence, focusing on workforce and patient happiness. - Healthcare organizations must embrace multimodal AI integration within the next 36 months, utilizing the technology to automate routine tasks while allowing staff to work at their highest potential. - Simple solutions to improve workforce satisfaction, combined with consumer-centric approaches and AI automation, are key to achieving scalable revenue growth and enhanced care delivery.
- Four major NCI-designated cancer centers, including Dana-Farber and Memorial Sloan Kettering, have united to form the Cancer AI Alliance (CAIA) with $40 million in funding from tech giants AWS, Microsoft, NVIDIA, and Deloitte. - The alliance will utilize federated AI learning to analyze vast amounts of cancer data while maintaining privacy, enabling researchers to uncover new insights in tumor biology and treatment resistance. - CAIA, coordinated by Fred Hutch Cancer Center, aims to begin operations by end of 2024 with first insights expected by 2025, targeting an ambitious goal of $1 billion in resources over time.
